Arine Collaborates with Amazon Web Services (AWS) to Address Health Equity
AWS grant will enable Arine’s proprietary technology platform to develop solutions for vulnerable populations
SAN FRANCISCO, April 28, 2022 /PRNewswire/ — Arine, an intelligent drug optimization company, today announced that it has been selected for Amazon Web Services (AWS) $40 million global program supporting organizations that develop solutions to reduce health inequalities. Arine’s proprietary AI-powered platform ensures safe and effective drug therapy by synthesizing multi-dimensional data to develop personalized medication recommendations for vulnerable patient populations, including elderly, low-income patients and underrepresented patients.
Through the program, AWS provides credit and technical expertise to organizations around the world that leverage AWS to improve health outcomes and equity in any of the following areas: 1) improving access to health services for underserved communities; 2) addressing social determinants of health (SDoH) as a barrier to optimized care; and 3) leveraging data to promote more equitable and inclusive systems of care.
“Medication issues have a disproportionate impact on older, low-income and underrepresented minorities,” said Yoona Kim, PhD, PharmD, Arine co-founder and CEO. “Arine’s platform proactively guides personalized interventions that overcome barriers to care, including language, economics and health literacy challenges. We see AWS as the ideal partner in our efforts to expand access to medicines and reduce healthcare inequities.
Arine plans to use the AWS grant to continue evaluating the impact of SDoH on medication-taking behaviors to maximize the benefits of drug therapy and improve outcomes. Using the company’s technology platform, Arine will integrate data collected through the program into risk stratification models that assess clinical, behavioral and social risks to identify those in need.
The program will also allow Arine to assess which therapeutic interventions will have the greatest impact on improving health and economic outcomes. “This information will help us identify disparities across different subgroups, giving further impetus to our efforts to improve outcomes in these vulnerable patient populations,” Dr. Kim commented.
Arine optimizes drug therapy and treatment plans, saving one in every six dollars spent on healthcare. The Company’s Medication Optimization Platform aggregates and analyzes clinical, social and behavioral data to identify and address gaps in patient care on behalf of at-risk payers and providers. Arine uses predictive analytics to target care to at-risk health plan members, AI to generate personalized care plans for each patient, and machine learning to continuously optimize member drug therapy. Clients have seen a 15% reduction in total cost of care and a 40% reduction in hospital admissions, while improving care team efficiency five to ten times. For more information, visit www.arine.io or follow us on LinkedIn.